Trevor S. Barlowe , Chelsea Anderson , Robert S. Sandler , Disha Subramaniam , Alicia Muratore , John B. Buse , Lindsey N. Gouker , Rajiv T. Majithia , Nicholas J. Shaheen , Til Stürmer , Michael K. Dougherty
{"title":"Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes","authors":"Trevor S. Barlowe , Chelsea Anderson , Robert S. Sandler , Disha Subramaniam , Alicia Muratore , John B. Buse , Lindsey N. Gouker , Rajiv T. Majithia , Nicholas J. Shaheen , Til Stürmer , Michael K. Dougherty","doi":"10.1016/j.cgh.2024.04.038","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & Aims</h3><div>Glucagon-like peptide-1–receptor agonists (GLP1-RAs) have been associated with greater retention of gastric contents, however, there is minimal controlled, population-based data evaluating the potential adverse effects<span> of GLP1-RA in the periprocedural setting. We aimed to determine if there is increased risk of aspiration and aspiration-related complications after upper endoscopy in patients using GLP1-RAs.</span></div></div><div><h3>Methods</h3><div><span>We used a nationwide commercial administrative claims database to conduct a retrospective cohort study<span> of patients aged 18 to 64 with type 2 diabetes who underwent outpatient upper endoscopy from 2005 to 2021. We identified 6,806,046 unique upper endoscopy procedures. We compared claims for aspiration and associated pulmonary adverse events in the 14 days after upper endoscopy between users of GLP1-RAs, </span></span>dipeptidyl peptidase 4 inhibitors<span><span><span> (DPP4is), and chronic opioids. We adjusted for age, sex, Charlson Comorbidity score, underlying </span>respiratory disease, and </span>gastroparesis.</span></div></div><div><h3>Results</h3><div>We found that pulmonary adverse events after upper endoscopy are rare, ranging from 6 to 25 events per 10,000 procedures. When comparing GLP1-RAs with DPP4i, crude relative risks of aspiration (0.67; 95% CI, 0.25–1.75), aspiration pneumonia<span> (0.95; 95% CI, 0.40–2.29), pneumonia (1.07; 95% CI, 0.62–1.86), or respiratory failure (0.75; 95% CI, 0.38–1.48) were not higher in patients prescribed a GLP1-RA. When comparing GLP1-RAs with opioids, crude relative risks were 0.42 (95% CI, 0.15–1.16) for aspiration, 0.60 (95% CI, 0.24–1.52) for aspiration pneumonia, 0.30 (95% CI, 0.19–0.49) for pneumonia, and 0.24 (95% CI, 0.13–0.45) for respiratory failure. These results were consistent across several sensitivity analyses.</span></div></div><div><h3>Conclusions</h3><div>GLP1-RA use is not associated with an increased risk of pulmonary complications after upper endoscopy compared with DPP4i use in patients with type 2 diabetes.</div></div>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"23 5","pages":"Pages 739-747"},"PeriodicalIF":11.6000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1542356524004531","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background & Aims
Glucagon-like peptide-1–receptor agonists (GLP1-RAs) have been associated with greater retention of gastric contents, however, there is minimal controlled, population-based data evaluating the potential adverse effects of GLP1-RA in the periprocedural setting. We aimed to determine if there is increased risk of aspiration and aspiration-related complications after upper endoscopy in patients using GLP1-RAs.
Methods
We used a nationwide commercial administrative claims database to conduct a retrospective cohort study of patients aged 18 to 64 with type 2 diabetes who underwent outpatient upper endoscopy from 2005 to 2021. We identified 6,806,046 unique upper endoscopy procedures. We compared claims for aspiration and associated pulmonary adverse events in the 14 days after upper endoscopy between users of GLP1-RAs, dipeptidyl peptidase 4 inhibitors (DPP4is), and chronic opioids. We adjusted for age, sex, Charlson Comorbidity score, underlying respiratory disease, and gastroparesis.
Results
We found that pulmonary adverse events after upper endoscopy are rare, ranging from 6 to 25 events per 10,000 procedures. When comparing GLP1-RAs with DPP4i, crude relative risks of aspiration (0.67; 95% CI, 0.25–1.75), aspiration pneumonia (0.95; 95% CI, 0.40–2.29), pneumonia (1.07; 95% CI, 0.62–1.86), or respiratory failure (0.75; 95% CI, 0.38–1.48) were not higher in patients prescribed a GLP1-RA. When comparing GLP1-RAs with opioids, crude relative risks were 0.42 (95% CI, 0.15–1.16) for aspiration, 0.60 (95% CI, 0.24–1.52) for aspiration pneumonia, 0.30 (95% CI, 0.19–0.49) for pneumonia, and 0.24 (95% CI, 0.13–0.45) for respiratory failure. These results were consistent across several sensitivity analyses.
Conclusions
GLP1-RA use is not associated with an increased risk of pulmonary complications after upper endoscopy compared with DPP4i use in patients with type 2 diabetes.
期刊介绍:
Clinical Gastroenterology and Hepatology (CGH) is dedicated to offering readers a comprehensive exploration of themes in clinical gastroenterology and hepatology. Encompassing diagnostic, endoscopic, interventional, and therapeutic advances, the journal covers areas such as cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion.
As a peer-reviewed publication, CGH features original articles and scholarly reviews, ensuring immediate relevance to the practice of gastroenterology and hepatology. Beyond peer-reviewed content, the journal includes invited key reviews and articles on endoscopy/practice-based technology, health-care policy, and practice management. Multimedia elements, including images, video abstracts, and podcasts, enhance the reader's experience. CGH remains actively engaged with its audience through updates and commentary shared via platforms such as Facebook and Twitter.